[Federal Register Volume 85, Number 95 (Friday, May 15, 2020)]
[Notices]
[Pages 29457-29458]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-10408]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-20-19BHC]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled National Evaluation of the DP18-1815
Cooperative Agreement Program: Category A, Diabetes Management and Type
2 Diabetes Prevention to the Office of Management and Budget (OMB) for
review and approval. CDC previously published a ``Proposed Data
Collection Submitted for Public Comment and Recommendations'' notice on
July 5, 2019, to obtain comments from the public and affected agencies.
CDC did not receive comments related to the previous notice. This
notice serves to allow an additional 30 days for public and affected
agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
National Evaluation of the DP18-1815 Cooperative Agreement Program:
Category A, Diabetes Management and Type 2 Diabetes Prevention--New--
National Center for Chronic Disease Prevention and Health Promotion
(NCCDPHP), Centers for Disease Control and Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and Prevention (CDC) Division of
Diabetes Translation (DDT) and Division for Heart Disease and Stroke
Prevention (DHDSP) are submitting this new information collection
request (ICR) for an evaluation of the recently launched five-year
Cooperative Agreement program CDC-RFA-DP18-1815PPHF18: Improving the
Health of Americans Through Prevention and Management of Diabetes and
Heart Disease and Stroke, hereafter referred to as ``1815''. This
cooperative agreement funds all 50 State Health Departments and the
Washington, DC health department (hereafter referred to as ``HD
recipients'') to support investments in implementing evidence-based
strategies to prevent and manage cardiovascular disease (CVD) and
diabetes in high-burden populations/communities within each state and
the District of Columbia. High burden populations/communities are those
affected disproportionately by high blood pressure, high blood
cholesterol, diabetes, or prediabetes due to socioeconomic or other
characteristics, including access to care, poor quality of care, or low
income. The 1815 program is a collaboration between DDT and DHDSP and
is structured into two program categories aligning with each
[[Page 29458]]
Division: Category A focuses on diabetes management and type 2 diabetes
prevention; Category B focuses on CVD prevention and management. This
information request package focuses on data collection activities for
the Category A diabetes assessment.
This cooperative agreement is a substantial investment of federal
funds. DDT and DHDSP are responsible for the stewardship of these
funds, and they must be able to demonstrate the types of interventions
being implemented and what is being accomplished through the use of
these funds. Thus, throughout the five-year cooperative agreement
period, CDC will work with HD recipients to track the implementation of
the cooperative agreement strategies and evaluate program processes and
outcomes. In order to collect this information for Category A, CDC has
designed two overarching components: (1) Category A rapid evaluation of
DSMES and National DPP partner sites and (2) Category A recipient-led
evaluations. Each component consists of data collection mechanisms and
tools that are designed to capture the most relevant information needed
to inform the evaluation effort while placing minimum burden on
respondents. Respondents will include HD recipients, as well as select
HD recipient partner sites, which are organizations that HD recipients
are partnering with in the implementation of the 1815 strategies.
The evaluation of cooperative agreement strategies and activities
conducted by DDT will determine the efficiency, effectiveness, impact
and sustainability of 1815-funded strategies in the promotion,
prevention, and management of diabetes and heart disease and help
identify promising practices that can be replicated and scaled to
better improve health outcomes. In addition, evaluation plays a
critical role in organizational learning, program planning, decision-
making, and measurement of the 1815 strategies. As an action-oriented
process, the evaluation will serve to identify programs that have
positive outcomes, identify those that may need additional technical
assistance support, and highlight the specific activities that make the
biggest contribution to improving diabetes and cardiovascular disease
prevention and management efforts. Without collection of new evaluative
data, CDC will not be able to capture critical information needed to
continuously improve programmatic efforts and clearly demonstrate the
use of federal funds.
OMB approval is requested for three years. Participation is
required for cooperative agreement awardees and voluntary for partner
sites. The total estimated annualized burden hours are 1,084.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Type of respondent Form name respondents responses per response (in
respondent hours)
----------------------------------------------------------------------------------------------------------------
Health Department (1815 Recipient). Evaluation and Performance 17 1 8
Measurement Plan (EPMP).
Recipient-Led Evaluation 51 1 8
Reporting Template.
DSMES Partner Site-Level 17 1 0.5
Rapid Evaluation Rapid
Evaluation Form.
National DPP Partner Site- 17 1 0.5
Level Rapid Evaluation
Nomination Form.
DSMES Partner Site................. DSMES Partner Site-Level 340 1 0.5
Rapid Evaluation Survey
Questionnaire.
Program Coordinator 14 1 2
Interview Guide.
Professional Team Member 28 1 2
Interview Guide.
Paraprofessional Team 28 1 2
Member Interview Guide.
National DPP Partner Site.......... National DPP Partner Site- 340 1 0.5
Level Rapid Evaluation
Survey Questionnaire.
Program Coordinator 14 1 1
Interview Guide.
Lifestyle Coach Interview 28 1 1
Guide.
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2020-10408 Filed 5-14-20; 8:45 am]
BILLING CODE 4163-18-P